Meristem Family Wealth’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
$2.32M Sell
14,317
-2,920
-17% -$424K 0.25% 45
2021
Q4
$2.33M Buy
17,237
+43
+0.3% +$5.08K 0.2% 58
2021
Q3
$1.85M Buy
17,194
+4,014
+30% +$459K 0.18% 65
2021
Q2
$1.49M Buy
13,180
+4,359
+49% +$491K 0.23% 52
2021
Q1
$955K Sell
8,821
-2,199
-20% -$235K 0.19% 65
2020
Q4
$1.18M Buy
11,020
+2,202
+25% +$212K 0.25% 52
2020
Q3
$772K Sell
8,818
-369
-4% -$34.7K 0.2% 69
2020
Q2
$902K Sell
9,187
-476
-5% -$41.9K 0.25% 59
2020
Q1
$736K Sell
9,663
-45
-0.5% -$3.83K 0.23% 64
2019
Q4
$860K Buy
9,708
+383
+4% +$31.8K 0.21% 64
2019
Q3
$706K Sell
9,325
-4,577
-33% -$314K 0.19% 77
2019
Q2
$1.01M Buy
13,902
+4,843
+53% +$381K 0.31% 53
2019
Q1
$730K Sell
9,059
-18
-0.2% -$1.47K 0.25% 56
2018
Q4
$837K Buy
9,077
+56
+0.6% +$4.92K 0.31% 45
2018
Q3
$853K Buy
9,021
+1
+0% +$95 0.29% 44
2018
Q2
$836K Sell
9,020
-1,670
-16% -$163K 0.29% 45
2018
Q1
$1.01M Buy
10,690
+72
+0.7% +$7.91K 0.36% 40
2017
Q4
$1.03M Buy
10,618
+1
+0% +$94 0.37% 38
2017
Q3
$943K Sell
10,617
-199
-2% -$15.1K 0.38% 39
2017
Q2
$784K Buy
10,816
+1
+0% +$67 0.32% 47
2017
Q1
$705K Buy
10,815
+1
+0% +$63 0.28% 50
2016
Q4
$677K Sell
10,814
-1,947
-15% -$119K 0.28% 52
2016
Q3
$805K Buy
12,761
+746
+6% +$48.3K 0.34% 43
2016
Q2
$744K Buy
12,015
+1,116
+10% +$68K 0.33% 43
2016
Q1
$623K Sell
10,899
-116
-1% -$6.46K 0.28% 49
2015
Q4
$653K Hold
11,015
0.26% 47
2015
Q3
$599K Hold
11,015
0.31% 37
2015
Q2
$740K Hold
11,015
0.32% 44
2015
Q1
$645K Sell
11,015
-297
-3% -$17.9K 0.27% 54
2014
Q4
$740K Sell
11,312
-1,500
-12% -$94.6K 0.27% 52
2014
Q3
$740K Sell
12,812
-401
-3% -$22.3K 0.32% 44
2014
Q2
$746K Buy
13,213
+3
+0% +$157 0.31% 50
2014
Q1
$679K Sell
13,210
-1,436
-10% -$72.6K 0.3% 51
2013
Q4
$773K Buy
14,646
+1,338
+10% +$65.8K 0.32% 51
2013
Q3
$595K Sell
13,308
-406
-3% -$18K 0.27% 56
2013
Q2
$567K Buy
+13,714
New +$600K 0.26% 54

Other funds holding ABBV

Meristem Family Wealth's ABBV Position: Q1 2022 in Review

Meristem Family Wealth reduced its AbbVie (ABBV) stake by 17% in Q1 2022, selling an estimated $424K and leaving 14,317 shares worth $2.32M. The position accounts for 0.25% of the portfolio, ranked #45.

Meristem Family Wealth first reported a position in ABBV in Q2 2013 and has held it in 36 quarters since. The position peaked at $2.33M in Q4 2021. 3,053 funds tracked by Wall St. Rank hold ABBV as of Q1 2022.

  • Meristem Family Wealth held 14,317 shares of AbbVie worth $2.32M as of Q1 2022.
  • Meristem Family Wealth sold 2,920 AbbVie shares in Q1 2022, an estimated $424K.
  • AbbVie made up 0.25% of Meristem Family Wealth's portfolio in Q1 2022, its #45 holding.
  • Meristem Family Wealth first reported a position in AbbVie in Q2 2013 and has held it in 36 quarters since.
  • Meristem Family Wealth's AbbVie position peaked at $2.33M in Q4 2021.
  • 3,053 funds tracked by Wall St. Rank held AbbVie as of Q1 2022.

Based on Meristem Family Wealth's 13F filing for Q1 2022, filed 11 May 2022.